Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553359 | 0.99 | NLRP3 (0.36) | NLRP3MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL8206373 | 0.88 | NLRP3 (0.35) | NLRP3MEN1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL8579826 | 0.85 | MEN1 (0.33) | NLRP3MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL8578003 | 0.84 | MEN1 (0.32) | NLRP3MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL782117 | 0.84 | MEN1 (0.37) | NLRP3MEN1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL769209 | 0.84 | MEN1 (0.37) | NLRP3MEN1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL6306862 | 0.84 | MEN1 (0.37) | MEN1KMT2AL3MBTL1OPRM1 | |
| SCHEMBL8575814 | 0.84 | MEN1 (0.33) | NLRP3MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL12461036 | 0.82 | TSHR (0.31) | NLRP3MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL5490079 | 0.82 | L3MBTL1 (0.39) | MEN1KMT2ASMN1; SMN2CYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256158-B2 | 2,4,5,-trisubstituted phenylketo-enols for use as pesticides and herbicides | BAYER AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-6933261-B2 | 2,4,5-Trisubstituted phenylketoenols | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20050038021-A1 | 2,4,5,-trisubstituted phenylketo-enols for use as pesticides and herbicides | BAYER AG (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20030171219-A1 | 2,4,5-trisubstituted phenylketo-enols for use as pesticides and herbicides | LIEB FOLKER (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6511942-B1 | Animal husbandry, veterinary medicine | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-28 | — | — | US | disclosed |
| US-6110872-A | 3-(2,4,5-TRISUBSTITUTED PHENYL), 4-HYDROXY,5,5-(CYCLOALKYL OR HETEROCYCLOALKYL)PYRROLIN-2-ONE AND DERIVATIVES; METHOD OF MAKING BY INTRAMOLECULAR CONDENSATION OF SPECIFIED COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038021-A1 | 2,4,5,-trisubstituted phenylketo-enols for use as pesticides and herbicides | DDT, CYP4X1, PDHX | NLRP3 2340/4885MEN1 4803/4885KMT2A 409/4885 |
| US-20030171219-A1 | 2,4,5-trisubstituted phenylketo-enols for use as pesticides and herbicides | DDT, CYP4X1, HPD | NLRP3 2885/4885MEN1 4719/4885KMT2A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.